Mark Earl Hensley, Chief Operating Officer of Heron Therapeutics, Inc. /DE/ (NASDAQ:HRTX), filed a Form 4 on November 10, 2026, reporting changes in beneficial ownership stemming from restricted stock unit activity dated November 6, 2026.

Key Highlights

  • RSU conversion: 31,250 restricted stock units were converted to common stock on November 6, 2026, via transaction code M.
  • Shares withheld for taxes: 8,889 shares of common stock were disposed of on November 6, 2026, at $0.29 per share via transaction code F.
  • Post-transaction common stock: Hensley directly holds 201,683 shares of common stock following the reported transactions.
  • Remaining RSUs: 312,500 restricted stock units remain beneficially owned directly by Hensley after the reported activity.
  • Vesting schedule: The RSUs vest 25% on the first anniversary of the grant date (May 6, 2025), then in twelve equal quarterly installments thereafter.
  • Signing authority: The form was signed by Kathryn Lester as attorney-in-fact for Mark E. Hensley on November 10, 2026.

Hensley's RSU Activity and Resulting Ownership at Heron Therapeutics

According to the filing, Heron Therapeutics, Inc. /DE/ (NASDAQ:HRTX) Chief Operating Officer Mark Earl Hensley reported two transactions in common stock and one derivative security transaction on November 6, 2026. In Table I, 31,250 shares were acquired via transaction code M, reflecting the conversion of restricted stock units into common stock. A separate disposition of 8,889 shares was reported at $0.29 per share under transaction code F, which typically reflects shares withheld to cover tax obligations at the time of vesting. Following these transactions, Hensley directly holds 201,683 shares of common stock.

In Table II, the filing reports that the 31,250 restricted stock units involved in the conversion carried a conversion or exercise price and derivative security price both listed as $0 in the form, and that 312,500 restricted stock units remain directly beneficially owned by Hensley after the transaction. The filing states, per footnote 2, that the restricted stock units vest with 25% upon the first anniversary of the date of grant, which the filing identifies as May 6, 2025, and then in twelve equal quarterly installments thereafter. Heron Therapeutics is a biopharmaceutical company listed on NASDAQ under the symbol HRTX.

The filing was submitted on November 10, 2026, with Kathryn Lester signing as attorney-in-fact for Mark E. Hensley. The form covers only Hensley as an individual reporting person and was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934.

What Was Disclosed

This Form 4 discloses that COO Mark Earl Hensley of Heron Therapeutics (NASDAQ:HRTX) converted 31,250 restricted stock units into common stock on November 6, 2026, had 8,889 shares withheld at $0.29 per share, and directly retains 201,683 shares of common stock and 312,500 restricted stock units.